Version 1
: Received: 1 December 2023 / Approved: 4 December 2023 / Online: 4 December 2023 (14:49:46 CET)
How to cite:
Ferrari, I.V.; Di Mario, M. Amentoflavone: Exploring Potential Therapeutic Applications for Diabetes Mellitus. Preprints2023, 2023120222. https://doi.org/10.20944/preprints202312.0222.v1
Ferrari, I.V.; Di Mario, M. Amentoflavone: Exploring Potential Therapeutic Applications for Diabetes Mellitus. Preprints 2023, 2023120222. https://doi.org/10.20944/preprints202312.0222.v1
Ferrari, I.V.; Di Mario, M. Amentoflavone: Exploring Potential Therapeutic Applications for Diabetes Mellitus. Preprints2023, 2023120222. https://doi.org/10.20944/preprints202312.0222.v1
APA Style
Ferrari, I.V., & Di Mario, M. (2023). Amentoflavone: Exploring Potential Therapeutic Applications for Diabetes Mellitus. Preprints. https://doi.org/10.20944/preprints202312.0222.v1
Chicago/Turabian Style
Ferrari, I.V. and Mauro Di Mario. 2023 "Amentoflavone: Exploring Potential Therapeutic Applications for Diabetes Mellitus" Preprints. https://doi.org/10.20944/preprints202312.0222.v1
Abstract
Diabetes mellitus is acknowledged as a significant contributor to severe complications. The present work has explorated the potential role amentoflavone as an aldose reductase inhibitor through Docking Simulations. From these results this compound has shown excellent results with this enzyme with a high binding energy of -11 kcal/mol. If amentoflavone,a natural biflavonoid, proves effective in inhibiting aldose reductase, it could hold therapeutic promise for managing diabetic complications. However, it's crucial to emphasize that while computational studies offer valuable insights, experimental validation is essential to confirm the actual inhibitory effects and to establish the safety and efficacy of amentoflavone for this purpose. Further research and clinical studies are warranted to fully understand and harness the potential therapeutic benefits of amentoflavone in the context of diabetes.
Medicine and Pharmacology, Dietetics and Nutrition
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
